Analyst consensus rating
Integra LifeSciences Holdings Analyst Rating: Hold
Direct answer
Integra LifeSciences Holdings's consensus rating is Hold.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $19.56.
Forecast evidence checked September 8, 2026.
Get free Integra LifeSciences Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.26
- Average price target
- $19.56
- High price target
- $27.00
- Low price target
- $14.00
- Low target gap
- -13.9%
- Target upside
- +20.3%
- High target gap
- +66.1%
- Target range width
- 80%
- Consensus rating
- Hold
- Analysts
- 9
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Integra LifeSciences Holdings?
Integra LifeSciences Holdings has a verified Hold consensus. The same dataset has an average price target of $19.56.
How far are Integra LifeSciences Holdings's low and high targets from the recorded price?
The low target implies -13.9%, while the high target implies +66.1%.
How many analysts are included in Integra LifeSciences Holdings's consensus?
The verified consensus includes 9 analysts.
How is Integra LifeSciences Holdings's target upside or downside calculated?
The average target of $19.56 is divided by the recorded price of $16.26, then one is subtracted to produce +20.3%. This does not guarantee a future return.
When was Integra LifeSciences Holdings's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.